Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation von RISCHIN, Danny, BIBBY, David C, CHONG, Geoff, KREMMIDIOTIS, Gabriel, LESKE, Annabell F, MATTHEWS, ClaytonA, WONG, ShirleyS, ROSEN, Mark A, DESAI, Jayesh

Volltext

Interlaboratory Reproducibility of Standardized Hemagglutination Inhibition Assays von Bibby, David C, Savanovic, Michael, Zhang, Jinrong, Torelli, Alessandro, Jeeninga, Rienk E, Gagnon, Luc, Harris, Shannon L

Volltext

Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice von Bibby, David C., Talmadge, James E., Dalal, Milind K., Kurz, Scott G., Chytil, Kevin M., Barry, Stephen E., Shand, David G., Steiert, Matthias

Volltext

In vitro study of GDNF release from biodegradable PLGA microspheres von Aubert-Pouëssel, Anne, Venier-Julienne, Marie-Claire, Clavreul, Anne, Sergent, Michelle, Jollivet, Christophe, Montero-Menei, Claudia N., Garcion, Emmanuel, Bibby, David C., Menei, Philippe, Benoit, Jean-Pierre

Volltext

A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma von Pal, Sumanta, Azad, Arun, Bhatia, Shailender, Drabkin, Harry, Costello, Brian, Sarantopoulos, John, Kanesvaran, Ravindran, Lauer, Richard, Starodub, Alexander, Hauke, Ralph, Sweeney, Christopher J, Hahn, Noah M, Sonpavde, Guru, Richey, Stephen, Breen, Timothy, Kremmidiotis, Gabriel, Leske, Annabell, Doolin, Elizabeth, Bibby, David C, Simpson, Jeremy, Iglesias, Jose, Hutson, Thomas

Volltext

A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma von Nowak, Anna K, Brown, Chris, Millward, Michael J, Creaney, Jenette, Byrne, Michael J, Hughes, Brett, Kremmidiotis, Gabriel, Bibby, David C, Leske, Annabell F, Mitchell, Paul L.R, Pavlakis, Nick, Boyer, Michael, Stockler, Martin R

Volltext

Encapsulation of protamine sulphate compacted DNA in polylactide and polylactide–co-glycolide microparticles von Dunne, Mairéad, Bibby, David C., Jones, Joanna C., Cudmore, Sally

Volltext

A novel in vitro delivery system for assessing the biological integrity of protein upon release from PLGA microspheres von AUBERT-POUËSSEL, Anne, BIBBY, David C, VENIER-JULIENNE, Marie-Claire, HINDRE, Francois, BENOIT, Jean-Pierre

Volltext

Poly(acrylic acid) microspheres containing β-cyclodextrin: loading and in vitro release of two dyes von Bibby, David C, Davies, Nigel M, Tucker, Ian G

Volltext

Mechanisms by which cyclodextrins modify drug release from polymeric drug delivery systems von Bibby, David C., Davies, Nigel M., Tucker, Ian G.

Volltext

Investigations into the structure and composition of β-cyclodextrin/poly(acrylic acid) microspheres von Bibby, David C, Davies, Nigel M, Tucker, Ian G

Volltext

Abstract 2774: Anti-cancer activity of the tumor-selective, hypoxia-inducing, agent BNC105 in platinum resistant ovarian cancer von Lavranos, Tina C., Leske, Annabell F., Inglis, Daniel J., Brown, Chloe K., Bibby, David C., Kremmidiotis, Gabriel

Volltext

Association of baseline IL-8 and ferritin with clinical outcome with everolimus and BNC105P in the DisrupTOR-1 trial von Pal, Sumanta Kumar, Azad, Arun, Bhatia, Sumeet, Drabkin, Harry A., Costello, Brian Addis, Sarantopoulos, John, Kanesvaran, Ravindran, Lauer, Richard C., Sweeney, Christopher, Hahn, Noah M., Sonpavde, Guru, Richey, Stephen Lane, Breen, Timothy, Kremmidiotis, Gabriel, Leske, Annabell F., Doolin, Elizabeth E., Bibby, David C., Simpson, Jeremy Andrew, Iglesias, Jose Luis, Hutson, Thomas E.

Volltext

A phase I/II study of the vascular disrupting agent BNC105P in combination with gemcitabine-carboplatin in partially platinum-sensitive ovarian cancer patients in first or second r... von Rischin, Danny, Matei, Daniela, Goh, Jeffrey C., Vaughan, Michelle Margaret, Beale, Philip James, Tenney, Meaghan Elizabeth, Martyn, Julie, Sommeijer, Dirkje Willemien, Iglesias, Jose Luis, Bibby, David C., Simpson, Jeremy, Doolin, Elizabeth E., Williams, Corinne E., Stockler, Martin R.

Volltext

A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC) patients: Updated phase I results of the Disruptor-1 trial von Sarantopoulos, John, Dang, Long H., Lauer, Richard C., Starodub, Alexander, Hauke, Ralph J., Galsky, Matt D., Bylow, Kathryn A., Cowey, Charles Lance, Bibby, David C., Kremmidiotis, Gabriel, Doolin, Elizabeth E., Lavranos, Tina C., Iglesias, Jose Luis, Sonpavde, Guru, Logan, Theodore, Hahn, Noah M., Sweeney, Christopher, Hutson, Thomas E.

Volltext

Updated phase I results of a phase I/II trial of BNC105P with everolimus in patients with metastatic renal cell carcinoma (mRCC) von Hutson, Thomas E., Dang, Long H., Lauer, Richard C., Starodub, Alexander, Hauke, Ralph J., Galsky, Matt D., Bylow, Kathryn A., Cowey, Charles Lance, Bibby, David C., Kremmidiotis, Gabriel, Doolin, Elizabeth E., Lavranos, Tina C., Sonpavde, Guru, Logan, Theodore, Hahn, Noah M., Sweeney, Christopher, Sarantopoulos, John

Volltext

Phase I results of a phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC) patients previously treated with VEGFR tyrosine kinase inhibitors von Hutson, Thomas E., Dang, Long H., Lauer, Richard C., Starodub, Alexander, Hauke, Ralph J., Galsky, Matt D., Bylow, Kathryn A., Logan, Theodore, Cowey, Charles Lance, Bibby, David C., Kremmidiotis, Gabriel, Doolin, Elizabeth E., Lavranos, Tina C., Sonpavde, Guru, Hahn, Noah M., Sweeney, Christopher, Sarantopoulos, John

Volltext

Phase II trial of BNC105P as second-line chemotherapy for advanced malignant pleural mesothelioma (MPM): Australasian Lung Cancer Trials Group and NHMRC Clinical Trials Centre Coll... von Nowak, Anna K., Brown, Chris, Millward, Michael, Hughes, Brett Gordon Maxwell, Bibby, David C., Kremmidiotis, Gabriel, Doolin, Elizabeth E., Mitchell, Paul, Pavlakis, Nick, Coskinas, Xanthi, Sebastian, Lucille T, Cummins, Michelle M, Boyer, Michael J., Parnis, Francis, Lavranos, Tina C., Stockler, Martin R.

Volltext

Phase I/II study of a BNC105P/everolimus regimen for progressive metastatic renal cell carcinoma (mRCC) following prior tyrosine kinase inhibitors (Hoosier Oncology Group) von Hutson, Thomas E., Dang, Long H., Lauer, Richard C., Starodub, Alexander, Hauke, Ralph J., Logan, Theodore, Bylow, Kathryn A., Galsky, Matt D., Bibby, David C., Kremmidiotis, Gabriel, Doolin, Elizabeth E., Lavranos, Tina C., Leske, Annabell F., Hahn, Noah M., Sonpavde, Guru, Sweeney, Christopher, Sarantopoulos, John

Volltext

A THERAPEUTIC PROTOCOL FOR TREATING OVARIAN CANCER von Kremmidiotis Gabriel, BIBBY David C, RISCHIN Danny

Volltext bestellen